Preservation of Human T Cell Membrane Integrity after Drying and Rehydration by Langford, Alex
Preservation of Human T Cell Membrane Integrity  
after Drying and Rehydration 
By 
Alex Jacob Langford 
 
Submitted to the graduate degree program in Pharmaceutical Chemistry and the Graduate 
Faculty of the University of Kansas in partial fulfillment of the requirements 





















Date Defended: August 12th, 2019 
ii 
 
The thesis committee for Alex Jacob Langford certifies that this is the approved version of the 
following thesis:   
 
Preservation of Human T Cell Membrane Integrity  




























 The biopharmaceutical industry has reached new frontiers in its ability to produce 
complex novel modalities for therapeutic application. Novel cell-based therapies offer a 
promising treatment for cancer by enabling T cells to target tumor antigens through ex vivo 
engineering of cell receptors and intracellular signaling domains. Development of cell-based 
therapeutics for clinical and commercial application requires successful manufacturing, stability, 
and transport. Since significant cell degradation occurs without the use of cryopreservation 
techniques, cells must be stored at extremely low temperatures (<-130 °C). Successful 
preservation of human T cells in the dried state provides the opportunity for non-vapor phase 
storage of the final product. Herein, several key factors are discussed and evaluated for T cell 
stabilization in the dried state, including the presence of intracellular stabilizer, cell health prior 
to drying, reconstitution procedure, and formulation components.  Residual water content of 
dried preparations was balanced between increased glass transition temperatures at low moisture 
and reduced process loss at high moisture. A vacuum-foam drying method demonstrated 
improved process recovery and increased stability at refrigerated storage compared to other 
drying techniques. These findings demonstrate the feasibility of drying human T cells with 
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 Since the discovery of recombinant DNA technology in the 1970s,1 the pharmaceutical 
industry has seen a significant shift from chemically synthesized drugs towards biologics. Some 
of the earliest FDA-approved biologics include recombinant insulin (Humulin, Eli Lilly) and the 
first monoclonal antibody muromonab-CD3 (anti-CD3) which were approved in 1982 and 1986, 
respectively.2, 3 As disease pathways and cancer targets become better understood and methods 
in bioengineering improve, the diversity and complexity of biopharmaceuticals evaluated in 
clinical trials have continued to increase.  
 One driver for the evaluation of novel therapeutic modalities is the pursuit of improved 
mechanisms for leveraging the immune system to treat cancer. Anti-CD20 monoclonal antibody 
(mAb) rituximab was approved by the FDA in 1997 and showed early success for the treatment 
of lymphoid malignancies. This encouraged development of other innovative therapies, including 
novel mAbs, bispecific T cell engager antibodies, and chimeric antigen receptor (CAR) T cell 
therapies.4 Immunotherapeutic modalities offer new options for treating cancer in addition to 
those previously available to the health care industry, such as tumor resection, chemotherapy, 
and radiation therapy.  
 While there are several immunotherapies on the market and in clinical development with 
the same end goal of improving cancer treatment for patients, the focus of this work is on novel 
engineered cellular therapies. CAR T cell therapies enable cytotoxic T lymphocytes to target 
tumor antigens by engineering cell receptors with an extracellular antigen-binding single chain 
variable fragment (scFv) coupled to intracellular T cell signaling domains.5 Maus et al.6 
reviewed the application of CAR T cells as an emerging oncology therapy for hematologic 
malignancies after 14 clinical trial reports were published. It was noted that the most effective 
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CAR design resulted in CAR T cells persisting and expanding in vivo for several weeks post-
infusion. A summation of the trial data showed an 80% response rate in acute lymphatic 
leukemia.  
 In 2017, the first CAR T cell therapies were approved by the FDA (Kymriah® and 
Yescarta®) for treatment of relapsed or refractory B-cell leukemia and lymphoma.7, 8 Beyond 
hematologic malignancies, it was reported that CAR T cells targeting interleukin-13 receptor 
alpha 2 (IL13Rα2) resulted in regression of intracranial and spinal tumors in a patient with 
recurrent multifocal glioblastoma who had previously, but unsuccessfully, received standard-of-
care treatment.9 This data suggests that T cell therapies can have strong antitumor efficacy 
against “difficult-to-treat” solid tumors. 
 Accompanying the promise of novel therapies are new challenges with regards to 
development and manufacturing. One challenge in particular for the development of 
biotherapeutic compounds is the stability, or shelf life, of the final drug product during shipping 
and storage.  For many years, the complexity of recombinant protein liabilities (both chemical 
and physical) led many products to utilize a solid dosage form to extend the shelf life.10 The 
traditional means of achieving a dried product has been freeze-drying, as evidenced by the large 
number of lyophilized products on the market.11 The freeze-drying process induces new stresses 
on a compound, such as interfacial (ice-water) stress and cryo-concentration during freezing, 
dehydration stress from the removal of bulk and bound water, and rehydration stress during 
reconstitution.11 Typically, for protein-based therapeutics, these challenges are overcome by the 
use of lyoprotectants, such as disaccharides and surfactants, and appropriate freeze-drying 
process design (e.g. product temperature < glass transition/collapse temperature). However, these 
approaches alone may not be sufficient for successful processing of more complex modalities, 
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such as cell-based therapies. Currently, stabilization of cell-based therapies is achieved by 
freezing in the presence of membrane permeable cryoprotectants, such as DMSO, glycerol, and 
ethylene glycol.12 These excipients enable the process of vitrification during freezing whereby 
ice crystal formation is inhibited and cells are stored in the glassy amorphous state. One 
challenge with the use of these excipients is their extremely low glass transition temperatures (<-
83 °C) which require vapor phase cryopreservation (<-130 °C) of the final product.13  
 Several discussions have been presented regarding the stabilization of mammalian cells 
in the dried state, including a chapter with the same title in the book Advances in Biopreservation 
that is now over a decade old.14 For drying of mammalian cells, much of the early discussion 
regarding stabilizing excipients has involved trehalose.15 Crowe et al.15 point to lessons from 
nature as one reason for focus on this particular excipient. Across a wide variety of anhydrobiotic 
species that can survive extreme desiccation, trehalose has been noted to accumulate at very high 
concentrations. While trehalose is prevalent in nature during anhydrobiosis, it is often not used 
during biopreservation since it does not readily diffuse across the cell membrane for stabilization 
of intracellular components. 
 Since the presence of stabilizer on both sides of the membrane is critical for cell 
stabilization during drying, procedures have been developed to load excipients, such as trehalose, 
into the intracellular matrix. Following an established procedure,16 Chen et al.17 introduced 
intracellular trehalose into mouse fibroblasts using a genetically engineered version of α-
hemolysin named H5 that reversibly generates permeable pores in the membrane. First, the 
authors demonstrated that the presence of high concentrations (0.2 and 0.4 M) of extracellular 
trehalose did not provide an improvement in post-dried cell membrane integrity in comparison to 
its absence. However, when intracellular trehalose was loaded by the aforementioned procedure, 
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the maintenance of membrane integrity post-drying (dried by natural convection and forced 
laminar flow) was reported to be achieved at and above trehalose concentrations of 0.2 M. This 
minimum concentration was reported to be in reasonable agreement with an estimate, based on 
cell diameter (~8 µm) and mass approximations, of 1.3 x 1010 trehalose molecules required to 
fully stabilize each cell. For formulations with sufficient intra- and extracellular trehalose, it was 
reported that significant membrane integrity was maintained when water content was >~15%, 
with drying beyond 15% leading to a drastic decrease in membrane integrity. Additionally, 
significant membrane integrity was maintained after storage at both -80 and -20 °C for several 
weeks.  Over the same time frame, significant losses in membrane integrity were observed at 
higher storage temperatures (4, 25, and 37 °C), which is likely due to storage above the glass 
transition temperature (Tg) of dried amorphous trehalose formulations at 15% residual water 
content. The Tg of amorphous trehalose at 15% (w/w) residual water content was estimated 
between -20 and -10 °C based on Figure 1 from Ohtake and Wang18.  It is noteworthy that these 
water content values are significantly higher than typically utilized for protein and virus 
stabilization in the dried state.19-23 This data demonstrates that the presence of intracellular 
stabilizer is critical for stabilization of cells during drying. 
 Buchanan et al.13 reported the stabilization of hematopoietic stem and progenitor cells 
(HPC) using trehalose loaded via endogenous cell surface receptors. Clonogenic activity was 
measured by utilizing the colony forming unit (CFU) assay. The cells were prepared in a 
formulation containing 6.8% trehalose, 2% hydroxyethyl starch and 5% human serum albumin. 
Trehalose-loaded HPC samples were taken throughout the freeze-drying process and compared 
to control cells. Through the freezing and primary drying steps, HPC were reported to be stable 
(i.e. no significant change in CFU). Significant losses in CFU were observed during the 
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secondary drying step. Evaluation of 5, 10, 15, and 20 °C secondary drying temperatures 
demonstrated a direct correlation between loss in CFU and drying temperature. Residual water 
content was decreased as secondary drying temperature was increased and a significant decrease 
in clonogenic potential was observed when samples were dried below 15% residual water 
content. These previous examples13, 17 highlight the need to optimize drying temperatures and 
residual water content to successfully stabilize cells in the dried state. 
 Natan et al.24 reported an optimized freeze-dried formulation of mononuclear cells 
derived from human umbilical cord blood. A combination of 0.1 M trehalose and 0.945 mg mL-1 
epigallocatechin gallate (EGCG, an antioxidant) resulted in a post-freeze-dried viability of 
91.6% before washing and 62.6% after washing. This was a significant improvement to a 
formulation with 0.1 M trehalose alone (18.5% and 10.3% before and after washing respectively) 
and to a formulation with 0.945 mg mL-1 EGCG alone (44.8% and 33.4% before and after 
washing respectively). Interestingly, this study did not evaluate the effect of intracellular 
trehalose which was previously reported to stabilize mammalian cells in the dried state in the 
absence of any antioxidant. This example demonstrates the complexity of and potential multi-
faceted approach necessary to stabilize mammalian cells in the dried amorphous state.  
 With the emergence of new therapeutic modalities in pharmaceutical development, it will 
be necessary for the formulation and drying parameters of each unique product to be 
adapted/optimized for successful stabilization. As interest in cell-based therapies continues to 
grow, significant improvements in manufacturing and storage are required. Currently, there is a 
paucity of literature evaluating the stabilization of T cells in the dried state. One publication 
evaluated the effect of residual moisture content on Jurkat Clone E6-1 cell viability after 
microwave-assisted drying in trehalose solutions.25 Similar to previous studies, dramatic 
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reductions in post-rehydration cell viability were observed when T cell samples were dried 
below approximately 20% (wet basis) residual water content. 
 As discussed above, freeze-drying is the most common drying method used for 
improving storage stability of biopharmaceuticals. However, the freezing step in the freeze-
drying process may damage cells during processing without the presence of membrane 
permeable excipients (e.g. DMSO). Since these excipients pose challenges during drying due to 
their low glass transition temperature, a drying technology that avoids freezing prior to 
dehydration may be beneficial for successful cell desiccation. In 2014, Walters et al.26 reviewed 
the current state of next-generation drying technologies for biopharmaceutical application and 
compared them to freeze-drying. There exists an abundance of drying technologies available for 
industrial applications including; convection drying, fluid bed drying, spray drying, microwave 
drying, vacuum drying, foam drying, and supercritical fluid drying. However, the need to 
maintain stability of labile biopharmaceuticals, aseptic processing, and scalability has limited the 
number of drying technologies available to the biopharmaceutical industry. 
 A recent evaluation of drying technologies compared the stability of live attenuated 
influenza vaccine (LAIV)27 after freeze-drying, spray drying, and vacuum-foam drying. The 
storage stability of the live attenuated Type-A H1N1 and B-strain influenza vaccines was 
assessed at various storage temperatures (4, 25, and 37 °C) using a TCID50 potency assay. At 4 
°C, the foam dried preparation exhibited a rate of titer loss of 0.006 log TCID50/mL/week 
compared to 0.014 log TCID50/mL/week and 0.028 log TCID50/mL/week for spray dried and 
freeze-dried preparations, respectively.  Foam dried preparations were significantly more stable 
than spray dried and freeze-dried preparations, while exhibiting low process loss and adequate 
retention of immunogenicity.  
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 Similarly, Abdul-Fattah et al.28 compared the stability of a genetically engineered 
bivalent live attenuated virus vaccine (Medi 534) after freeze-drying, spray drying and vacuum-
foam drying. The viral potency process loss of Medi 534 was greatest for freeze-dried material 
(1.4 log10 TCID50/mL) compared to spray dried (0.8 log10 TCID50/mL) and foam dried (0.8 log10 
TCID50/mL). The reason for increased process loss during freeze-drying was suggested to be 
greater susceptibility of the vaccine to the ice-water interface compared to the air-water interface 
encountered during foam drying and spray drying. During storage at 25 °C, vacuum-foam dried 
Medi 534 exhibited a lower rate of loss in potency than spray dried and freeze-dried materials. 
Abdul-Fattah and coauthors observed that improved storage stability of foam dried preparations 
was associated with decreased specific surface area and vaccine surface exposure. Based on 
these data and similar findings in other reports,29 vacuum-foam drying is considered a promising 
technique for stabilization of highly sensitive biological materials in the dried state.  
 Herein, naïve human T cells isolated from primary cells were used as a surrogate system 
to evaluate the feasibility of preserving engineered therapeutic T cells in the dried state. The 
intracellular trehalose concentrations in T cells after formulation in trehalose solutions was 
measured to ensure the presence of stabilizer on both sides of the cell membrane during drying. 
Vacuum-foam drying was developed and used to evaluate cell stabilization after drying and 
rehydration. Human T cell health was evaluated based on membrane integrity and cell count 
measurements. Membrane integrity data from vacuum-foam dried T cell preparations were 
compared to results from freeze-dried and spray freeze-dried preparations. 
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Materials & Methods 
T cell Sample Preparation 
 T cells used were primary human pan-T cells cryopreserved at -150 °C at a cell density of 
3E7 cells/mL. High purity α, α-trehalose di-hydrate was acquired from Pfanstiehl (Chicago, IL, 
USA), powder bovine serum albumin (BSA) was acquired from Fisher Scientific (BSA #1; Lot 
#: 185564) (Waltham, MA, USA) and Sigma-Aldrich (BSA #2; Lot #: SLBX7447) (St. Louis, 
MO, USA), 25% (w/v) human serum albumin (HSA) (Kenketsu Albumin 25, Lot #: N257N) was 
acquired from KM Biologics Co., Ltd. (formerly Kaketsuken) (Kumamoto, Japan), sodium 
chloride and sodium phosphate monobasic monohydrate were acquired from J.T. Baker. To 
prepare formulations, frozen T cells were thawed by holding vial in hand and diluted to target 
concentration in phosphate buffered saline (PBS). Then, cells were centrifuged for 10 minutes at 
≤1,000 x g, supernatant removed, and resuspended in the appropriate formulation matrix to a 
target cell density. Incubation of cells prior to formulation was performed by diluting cells to 
approximately 1E6 cells/mL in complete media (growth media + human serum with IL-6) and 
statically placing at 37 °C, 5% CO2 in a culture flask.   
Membrane Integrity and Cell Count Assay 
 Membrane integrity and cell count measurements were obtained using a NucleoCounter® 
3000 (NC-3000) (ChemoMetec A/S, Allerød, DK). Neat samples were typically diluted 4:1 in 
PBS (unless otherwise specified) and cell membrane integrity and count assays were performed 
using a Via1-Cassette™. The procedure uses membrane penetrating acridine orange (AO) and 
non-penetrating 4′,6-diamidino-2-phenylindole (DAPI) fluorescent dyes to assess cellular 
membrane integrity. Dried samples were equilibrated for no less than 30 minutes after 
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reconstitution prior to analysis. Initial studies showed increased variability when samples were 
measured immediately after reconstitution (data not shown). 
Protein and Trehalose Quantitation 
 Pierce™ BCA protein assay reagents from Thermo Scientific (Waltham, MA, USA) were 
used to measure protein concentration. Reagents were added and samples were incubated 
according to the manufacture’s protocol and absorbance was measured at 562 nm. Trehalose 
concentration was measured following the manufacturer’s protocol for a trehalose assay kit from 
Megazyme (Bray, Ireland). The assay quantitates glucose concentration spectroscopically 
(indirectly by the reduction of NADP+ to NADPH) before and after incubation with trehalase 
which hydrolyzes trehalose into two D-glucose molecules. Dilutions were made as needed to test 
samples in assay linear range of 0.02 to 0.4 mg mL-1 trehalose.  
Protein Marker Analysis 
 Cellular suspensions (1 mL) were centrifuged at 1,000 x g for 10 minutes, the supernatant 
was removed, and pellets were resuspended in water to lyse cells (using 250 or 500 uL). Samples 
were rapidly frozen in a -150 °C freezer to ensure complete lysis, thawed after 10 minutes and 
re-centrifuged at 15,000 x g for 5 minutes to remove the cellular debris. The supernatants were 
diluted and protein concentration was measured using BCA assay. 
Vacuum-Foam Drying 
 Vacuum-foam drying was performed using a LyoStar III lyophilizer (SP Scientific, 
Warminster, PA). Vacuum-foam drying cycles utilized pressures from 0.05 to 5 Torr and shelf 
temperatures from 5-30°C. There were two foam drying cycles used in this work. The first cycle 
(“standard cycle”) used a 10 mL vial with 1 mL fill volume. The partially stoppered vials were 
loaded onto a pre-equilibrated 20 °C shelf, vacuum was pulled to 5 Torr, shelf temperature was 
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ramped to 30 °C at 1 °C/min and held for 15-20 minutes. Then, the vacuum was pulled to 0.8 
Torr and held for varying times depending on the purpose of the experiment. The second cycle 
(“rapid cycle”) used a 2 mL vial with 100 µL fill volume and a nucleation site was added to 
facilitate rapid boiling (a piece of rubber stopper). The partially stoppered vials were loaded onto 
a pre-equilibrated 30 °C shelf, vacuum was pulled to 5 Torr and held for 20 minutes. After both 
cycles were complete, the pressure was increased to approximately 600 Torr and vials were 
stoppered prior to vacuum release. 
Freeze-Drying 
 Freeze-drying was performed using a LyoStar III lyophilizer (SP Scientific, Warminster, 
PA) and a 10 mL vial with 1 mL fill volume. The partially stoppered vials were loaded onto a 
shelf pre-equilibrated at 5 °C, the vials were equilibrated for up to 1 h, the shelf temperature was 
ramped to -50 °C at 1 °C/min and held for >1 h. The vacuum was pulled to 0.05 Torr and the 
shelf temperature was ramped at 0.5 °C/min to -30 °C for the primary drying step. The cycle was 
ended after the Pirani gauge reached equilibrium with the capacitance manometer.  After the 
cycle was complete, the pressure was increased to approximately 600 Torr and vials were 
stoppered prior to vacuum release. 
Spray Freeze-Drying 
 A Buchi B 290 spray nozzle was configured above a metal tray filled with liquid nitrogen 
and the product was pumped using a peristaltic pump through the spray nozzle with a nitrogen 
gas flow rate of 4 L/h for 90 seconds. The frozen material was loaded into a LyoStar III 
lyophilizer (SP Scientific, Warminster, PA) with a shelf pre-equilibrated at -50 °C. After the 
liquid nitrogen had completely evaporated, the vacuum was pulled to 0.05 Torr and the shelf 
temperature was ramped at 0.5 °C/min to -30 °C for the primary drying step. The cycle was 
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ended (no secondary drying) after 675 minutes (preliminary experiments were performed to 
determine cycle time required to reach target residual water content).  After the cycle was 
complete, the pressure was increased to approximately 500 Torr and the shelf temperature was 
ramped to 5 °C. Immediately after the camber pressure reached ambient condition, the tray was 
transferred into a dry box and product was manually filled into 10 mL vials. A schematic of the 
spray freeze-drying process is shown in Figure 6. 
Moisture Analysis 
 Mettler Toledo (Columbus, OH, USA) Karl Fischer Titration Moisture Analyzer (C30) 
was used to determine the percent of residual water content in dried samples. Samples were 
reconstituted using 50% MeOH / 50% formamide diluent and vortexed until dissolved. Titration 
was performed on reconstituted samples and the total weight of water for each sample was 
determined. Percent residual water content (wet basis, w.b.) was calculated by dividing the total 
water content by the total sample weight (solids content + residual water content). 
Differential Scanning Calorimetry   
 Prior to differential scanning calorimetry (DSC) scans, dried samples were ground, mixed 
and packed into a 40 µL aluminum pan in a dry box and hermetically seal with an aluminum lid. 
Heat flows were acquired using a Mettler Toledo (Columbus, OH, USA) DSC822e at 2.0 °C/min 
with temperature modulation amplitude of 0.25 °C and a period of 15-30 seconds. Heat flows 





Results & Discussion 
Chapter 1: Trehalose Uptake 
 Maintaining cellular membrane integrity after cells are exposed to drying and rehydration 
stress requires the presence of stabilizer on both sides of the membrane. Efficient delivery of 
trehalose across the cell membrane can be challenging due to poor permeability and transport of 
polar compounds across the lipid bilayer. Several strategies have been developed to efficiently 
transport trehalose across mammalian cell membranes, including electroporation,30 fluid-phase 
endocytosis,31 and microinjection.32 For example, Satpathy et al.33 utilized osmotic imbalance 
and incubation above the phospholipid phase transition to increase trehalose uptake in red blood 
cells. The authors reported low trehalose uptake at 4 °C, moderate uptake at 23 °C and the 
highest uptake at 37 °C; however, increasing incubation temperature directly correlated with rate 
of hemolysis. A different strategy employed by Abazari et al.34 was to increase the lipophilicity 
of trehalose by acetylation of hydroxyl groups. This strategy was used for rat hepatocytes and 
significant trehalose was found to accumulate intracellularly. The highest intracellular trehalose 
concentration was observed after incubation with trehalose hexaacetate which possessed the 
highest logP value. Trehalose quantitation showed that trehalose hexaacetate is deacetylated into 
trehalose inside the cell by intracellular esterases. Based on this mechanism, trehalose levels 
(combination of free and acetylated trehalose) reached 10-fold higher intracellularly compared to 
the extracellular environment. 
 The above methods demonstrate efficient transport of trehalose inside the cell. Since the 
primary drying process utilized in this work, namely vacuum-foam drying, requires notably high 
solids content, it was proposed to evaluate trehalose uptake using osmotic imbalance to force 
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sufficient amount of stabilizer across the cell membrane. The amount of intracellular trehalose 
taken up by human T cells at extracellular concentrations up to 300 mg mL-1 was evaluated. 
 Since bulk analyte concentration measurements are not able to distinguish extracellular 
and intracellular concentrations, intracellular components had to be separated from the 
extracellular matrix to accurately quantitate intracellular concentration. Additionally, accurate 
measurement of the cell concentration in the final sample preparation (i.e. after the extracellular 
matrix and lysed cells have been removed) required an analyte marker that correlated to cell 
density.  
 Jansen et al.35 evaluated both DNA and protein as analyte markers for peripheral blood 
mononuclear cell counting. The authors concluded that DNA was better suited as a cell counting 
marker; however, this was due to hemoglobin contamination (from red blood cells) in the whole 
blood samples impacting the protein marker results. Since protein contamination was not 
expected for the T cell samples used in this work, a protein analyte marker for cell counting was 
evaluated (same approach used by Abazari et al.34). 
 Cell count was measured using the NC-3000 cell count assay and samples were diluted in 
PBS to three different cell densities (1E6, 5E6 and 1E7). The protein marker concentration (after 
lysis) was measured and plotted against cell density (before lysis) in Figure 1. There was a 
strong correlation (>0.99 r2) between protein marker concentration and cell density. Based on 
these data, a protein marker was used as an indirect measure of cell density during trehalose 
uptake experiments. Measured protein concentrations at all cell densities were compared to an 
expected protein concentration value that assumed a cellular composition of 18% protein (Table 
2-3 in Alberts et al.36). The cellular protein concentration values were between 58 - 74% of the 
expected amount. The lower protein content per cell values than expected may be due to loss of 
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membrane and structural proteins during lysis and cell debris removal. The cellular protein 
content (µg protein/cell) was determined by dividing the micrograms of protein/mL preparation 
by the number of cells/mL. The average cellular protein content was 6.5E-5 ± 2.8E-6 µg protein / 
cell (calculated using protein marker preparations at 5E6 and 1E7 cells/mL, n = 7).  
 
Figure 1. Protein marker concentration (after lysis) and cell count (before lysis). 
 The rate and amount of intracellular trehalose uptake in human T cells at varying 
concentrations was evaluated. Cells were prepared at 5E6 cells/mL in 10 mM phosphate, 150 
mM NaCl at pH 7.4 (PBS) with trehalose concentrations ranging from 0 to 300 mg mL-1. Cell 
preparations were incubated at ambient conditions and 1.5 mL aliquots were taken at defined 
time intervals (0, 1, 2, 4, and 6 hr). Aliquots were washed twice by centrifuging for 5 minutes at 
3,000 x g, removing the supernatant and resuspending with 1.5 mL of 10 mg mL-1 sucrose in 
PBS (for osmotic balance). After the second wash, samples were centrifuged, the supernatant 
was removed, pellet was resuspended in 250 μL of water and then samples were frozen in a -150 
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°C freezer to lyse the cells. Preparations were thawed and centrifuged for 15 minutes at 15,000 x 
g to remove cellular debris. The supernatant was analyzed for trehalose and protein marker 
concentration. The cellular protein content from Figure 1 was used to estimate the intracellular 
trehalose concentration on a cellular basis. In order to determine the final milligrams of 
intracellular trehalose per milliliter, cellular volume was calculated using a cell diameter of 10 
µm (estimated from cell count data) and assuming spherical geometry. 
 Figure 2 shows concentration dependent trehalose uptake in human T cells. While the 
exact mechanism of uptake is not fully understood, fluid-phase endocytosis and facilitated 
diffusion were two of the mechanisms proposed. Oliver et al.31 demonstrated the fluid-phase 
endocytosis mechanism of trehalose uptake for human mesenchymal stem cells when stored 
above their first membrane phase transition temperature (15 °C).  
 
Figure 2. Kinetics of intracellular trehalose uptake in human T cells. Data presented as average 
± standard deviation (n = 3). 
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 After 6 hours of incubation, the 10 mg mL-1 extracellular formulation reached 
approximately 4.7 mg mL-1 intracellular trehalose. This data is in reasonable agreement with 
work by Abazari et al.34 which showed approximately 2 - 4 mg mL-1 (6 - 11 mM) trehalose were 
loaded intracellularly (for rat hepatocytes) using approximately the same extracellular trehalose 
concentration (10 mg mL-1). When extracellular trehalose was increased 10-, 20-, and 30-fold, a 
significant increase in trehalose uptake was observed. After 2 hours of incubation, intracellular 
trehalose concentrations of 8.4, 20.7 and 36.7 mg mL-1 were observed for 100, 200, and 300 mg 
mL-1 extracellular concentration formulations, respectively. The maximum intracellular trehalose 
observed was in 300 mg mL-1 extracellular trehalose; although, there was not a significant 
difference between the intracellular trehalose concentrations at 200 and 300 mg mL-1 after 6 
hours of incubation. 
 During red blood cell loading experiments, Satpathy et al.33 reported the lack of trehalose 
uptake below 600 mM (~205 mg mL-1) which suggested facilitated diffusion was not the 
mechanism of trehalose uptake. Sufficient energy to drive trehalose across the membrane was 
achieved at extracellular trehalose levels above 600 mM (~205 mg mL-1). When trehalose was 
loaded at nearly 300 mg mL-1 (274 mg mL-1) extracellular trehalose at 37 °C for 16 hours, 
intracellular trehalose levels were able to reach 65 mM (~22 mg mL-1). These data for red blood 
cells are in reasonable agreement (approximately 60% difference) with the results for T cells 
where, 200 and 300 mg mL-1 extracellular trehalose levels resulted in approximately 35 mg mL-1 
intracellular levels after 6 hr incubation at ~23 °C (ambient). In contrast to red blood cells, the 
results show that extracellular concentrations below 600 mM (i.e. 300 mM) are able to drive 
trehalose across the T cell membrane at ~23 °C (ambient) which may be due to differences in 
membrane composition of the two cell types. Additional variability in the intracellular 
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concentration results between these two studies may be due to differences in the assumptions 
(e.g. cell volume) required for the intracellular calculation. 
 T cell membrane integrity of preparations with 0 and 100 mg mL-1 extracellular trehalose 
dropped from approximately 86-88% to 82% following 6 hours of incubation at ~23 °C 
(ambient) during loading. The 300 mg mL-1 extracellular trehalose preparations had lower initial 
and 6 hours membrane integrity, which ranged between 78-80% at both time points (initial and 
after 6 hours).  
 These data demonstrate that a significant amount of trehalose can be loaded 
intracellularly in a relatively short period of time when formulated in extracellular trehalose 
concentrations ranging from approximately 100 to 300 mg mL-1. The cell stabilization data in the 
following sections was collected using 30% (300 mg mL-1) extracellular trehalose formulations 
due to the high success rate of vacuum-foam drying at this concentration. When lower trehalose 
formulations were evaluated, a combination of either freezing during vacuum-foam drying, low 
vacuum-foam drying success (discussed below) or poor membrane integrity results was observed 
(data not shown). These outcomes made it difficult to draw conclusions at lower concentrations 
of trehalose. Further studies would be required to optimize loading at reduced trehalose 
concentrations with improved liquid stability and vacuum-foam drying success. 
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Chapter 2: Drying Process Development 
 In 1913, Charles Campbell invented a process for drying milk that resulted in a light and 
porous material that dissolved more rapidly than powders produced from earlier processes.37 The 
process involved whipping or foaming a milk concentrate prior to drying the material by 
exposure to hot air. In 1943, Wilbert Heyman designed another foam drying process that utilized 
a high vacuum to boil a lemon extract and corn syrup mixture at lower temperatures until the 
bubbles began to solidify.38 The final product resulted in a dried foam structure which could be 
further dehydrated and ground to a desired particle size. Over the next half century, the process 
of drying a foamy material with the use of a vacuum (i.e. vacuum-foam drying) would be 
adapted to stabilize bacteria,39 live viruses,40 and other biologically active materials.41 This 
section describes the process development performed to utilize vacuum-foam drying, as well as 
freeze-drying and spray freeze-drying, in this work.   
 Vacuum-foam drying transforms a solution or suspension into a dried static foam through 
vacuum-induced evaporation and boiling. This differs from the primary dehydration process 
during freeze-drying, which is sublimation. Vacuum-foam drying enables removal of water by 
evaporation and boiling at low processing temperatures (e.g. <10 °C) through the application of a 
vacuum. For pharmaceutical development and manufacturing, this method can be performed 
using a lyophilizer capable of pressure control at a higher range than a typical freeze-drying 
cycle (e.g., 1-10 Torr). The vacuum-induced boiling process gradually solidifies the wet material 
resulting in a final dried foam with an expanded volume compared to a typical freeze-dried cake. 
Development of a foam dried biotherapeutic material often utilizes high concentration sugar 
formulations which depress the freezing point and increase the viscosity of the solution.40  
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Figure 3 shows that increasing sucrose concentration from 15 to 40% (w/v), while maintaining a 
1 mL fill, correlates with increasing volumes of the final dried foam.  
 
Figure 3. Vacuum-foam dried (VFD) preparations of 15%, 30%, and 40% sucrose (left to right). 
 An example of data from a laboratory vacuum-foam drying cycle used in this work is 
presented in Figure 4 (the cycle is similar to the standard cycle described in Materials & 
Methods). Partially stoppered vials were loaded onto a pre-equilibrated shelf at 20 °C, the 
pressure was decreased from ambient to 5000 mTorr (based on the capacitance manometer), the 
shelf temperature was ramped to 30 °C at 1 °C/min and held for 15 minutes. When the vacuum 
reached 5 Torr, the product temperature decreased below 10 °C due to the vapor pressure of 
water at this pressure. This decrease in pressure can either result in evaporation at the solution 
surface (i.e. vacuum dry) or a combination of boiling and evaporation (i.e. vacuum-foam drying). 
The boiling/foaming process during vacuum-foam drying increases the solution surface area and 
facilitates efficient removal of water. This process results in a lower residual water content of the 
final dried product compared to vacuum drying alone (data not shown). Therefore, development 
work is required prior to processing biological materials to ensure that the selected formulation is 




Figure 4. Vacuum-foam drying cycle data 
 After the 15-minute hold, the pressure was decreased from 5 Torr to 0.8 Torr and water 
continued to be removed by a combination of boiling and evaporation until it gradually 
solidified. As the rate of water removal decreased, evaporative cooling was reduced and the 
product temperature increased until it reached equilibrium near the shelf temperature (Figure 4). 
The initial foam drying phase is deemed complete once the Pirani pressure gauge reached 
equilibrium with the capacitance manometer (Figure 4). After the initial foam drying phase, 
residual water content can be reduced further through the desorption of water during a secondary 
drying step which is typically performed at a higher shelf temperature. The rate of water 
desorption is slower for a foam-dried material compared to a freeze-dried material and, therefore, 
longer secondary drying times may be required in order to achieve comparable residual water 
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content.42 A secondary drying step was typically not used in this work since low residual water 
content resulted in reduced membrane integrity of dried T cell preparations. 
 The formulation composition itself plays a significant role in the ability of the foam 
drying cycle to produce a dried foam. Depending on the formulation of the material being 
processed, the application of vacuum (e.g. from ambient to 5 Torr) may yield a dried thin-film 
(Figure 5a) instead of a foam structure. Some proteins, such as BSA, are known to promote 
foam formation43 and were hypothesized to improve foamability during the vacuum-foam drying 
process. The impact of BSA protein on the foamability of a 30% sucrose formulation during 
vacuum drying was evaluated (Figure 5). The drying cycle used a shelf temperature starting at 0 
°C during the initial pressure decrease from ambient to 5 Torr prior to ramping to 30 °C. The 
reduced temperature differential between shelf and product was previously shown to reduce 
foamability (data not shown) and, therefore, these conditions challenged the robustness of the 
formulations to foam formation. Figure 5 shows the final product after foam drying 300 mg mL-
1 sucrose solution with and without BSA at 30 mg mL-1 (10 mL vials with a 1 mL fill volume). 
While the sucrose solution alone did not result in foam formation, the addition of BSA 




Figure 5. Comparison of product appearance for 30% sucrose solution (a) and 30% sucrose, 3% 
BSA solution (b) after vacuum drying cycle.   
 These data show that formulations containing high concentration of sucrose can be 
robustly foam dried with the addition of 30 mg mL-1 BSA. The heterogeneity in vial-to-vial 
appearance from a vacuum-foam drying process is a challenge that should be considered during 
formulation optimization and process development.44 Additionally, vial-to-vial variability in 
foam success can be observed where some vials (containing the same formulation) within a 
given batch will successfully boil/foam while others within the same batch will not. During 
initial evaluations of this next-generation technology, formulations that consistently result in a 
foam dried product should be used and future work can be performed to address these additional 
challenges.  
 Freeze-drying and spray freeze-drying cycles were developed to target higher residual 
water content (~6-10% w.b.) than typically utilized for biotherapeutics. A freeze-drying cycle 
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with a conservative primary drying step and no secondary drying step was used to evaluate 
process loss and stability for freeze-dried preparations. A schematic overview of the laboratory 
scale spray freeze-drying process is shown in Figure 6. Spray freeze-drying cycle parameters are 
described in Materials & Methods. Similar to the freeze-drying cycle, the secondary drying step 
was not performed for the spray freeze-drying process. 
 
Figure 6. Laboratory Scale Spray Freeze-Drying Schematic 
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Chapter 3: Membrane Integrity after Drying and Rehydration 
 Membrane integrity of pre- and post-dried cell preparations was measured using a NC-
3000 Via1-Cassette™ membrane integrity and cell count assay. The procedure uses membrane 
penetrating acridine orange (AO) and non-penetrating 4′,6-diamidino-2-phenylindole (DAPI) 
fluorescent dyes to assess cellular membrane integrity (see Materials & Methods). After drying 
and rehydration, cells possessed varying levels of DAPI penetration. Figure 7 shows images of 
cells with varying AO to DAPI area ratios. Cells without DAPI observed were quantified as 
possessing membrane integrity. Cells with DAPI observed, even at significantly lower levels 
than AO, were quantified as not possessing membrane integrity. The varying levels of DAPI 
penetration may suggest variability in the structural damage induced on the cell population. 
 
Figure 7. Images from the NC-3000 membrane integrity and cell count assay. Membrane 
penetrating acridine orange (green) and non-penetrating 4′,6-diamidino-2-phenylindole (blue) are 
used to assess membrane integrity. 
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 Preserving membrane integrity can be challenging due to the many factors that play a role 
in maintaining an intact phospholipid bi-layer through drying and rehydration. Since 
cryopreserved cells were not in an optimal state immediately after thaw, the impact of 
subsequent recovery (i.e. incubation in media at 37 °C, 5% CO2) after the cells were thawed was 
evaluated. After recovery, cells were formulated at 5E6 cells/mL, 30% trehalose, 3% BSA #1 in 
PBS and membrane integrity was measured. While the primary purpose of trehalose in the 
formulation is cell stabilization, BSA was predominantly used for its favorable foaming 
properties (see Drying Process Development). It is noteworthy that albumin (human) is found in 
multiple approved CAR T cell therapy formulations45, 46 that are stored in the frozen state.  
 Membrane integrity of all 5E6 cells/mL cell preparations prior to drying was 
approximately 90% (after centrifugation and resuspension in the formulation matrix). However, 
prior to formulation, the number of cells per mL after 3 days of incubation in the culture flask 
was approximately double the initial (0 day) density, demonstrating cell proliferation during 
incubation. Using the standard foam drying cycle, 1 mL aliquots were dried to 10.4 ± 0.3% 
(average ± std, n = 2) residual water content (w.b.). After rehydration with water and 4:1 dilution 
in PBS (pH 7.4), samples were held for approximately one hour and membrane integrity was 
measured. While pre-drying membrane integrity was comparable for all samples, there was a 
significant improvement in membrane integrity for cells that were incubated for at least 1 day as 
opposed to dried immediately after being thawed (Figure 8). This data suggests that beyond pre-
drying membrane integrity, the overall health and growth phase of the cells prior to drying plays 




Figure 8. Impact of cell incubation time (prior to drying) on T cell membrane integrity after 
vacuum-foam drying (VFD) and rehydration. Data presented as average ± standard deviation    
(n =4) and compared to pre-dried samples (n = 2). 
 The drying time and kinetics were expected to play a significant role in preservation of 
membrane integrity throughout drying. To evaluate these parameters, cells were incubated for 1 
day, prepared in the same formulation (5E6 cells/mL, 30% trehalose, 3% BSA #1 in PBS) and 
dried using a rapid foam drying cycle (20-minute drying time). After the rapid drying cycle, the 
membrane integrity of the human T cells decreased 29.8% (89.0 ± 2.8% to 59.2 ± 3.5%) (Table 
1). Interestingly, the membrane integrity results were not significantly different from the 
previous data using a standard foam drying cycle (100-minute drying time), which resulted in a 
decrease of 30.7% (90.4 ± 0.9% to 59.7 ± 0.9%). This data suggests that the cell recovery in a 
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high concentration trehalose-based formulation was not significantly improved by reducing 
drying time.   
 Since at high trehalose concentrations a significant amount of trehalose is loaded into the 
intracellular space, the rehydration/dilution method was expected to have an impact on osmotic 
shock, swelling and potentially lysis of the cells. In 1959, Leach and Scott discussed the 
surprising fact that many researchers aiming to dry micro-organisms did not discuss the impact 
of rehydration method. Leach and Scott showed that the survival of dried bacteria was impacted 
by rehydration rate and concentration of solutes in the rehydration medium.47 Several later 
studies have also demonstrated the importance of rehydration medium and procedure on cell 
viability.48-50 Therefore, the impact of reconstitution procedure on cell membrane integrity after 
rehydration was evaluated.  
 Table 1 shows the impact of various reconstitution methods on the membrane integrity of 
dried cell preparations. The cells were dried at 5E6 cells/mL, 30% trehalose, 3% BSA #1 in PBS 
using the rapid drying cycle and a 100 µL fill volume. Method 1 was expected to result in the 
most significant osmotic shock (i.e. the largest differential in solute concentration across the 
membrane) since the matrix is rehydrated and diluted (4:1) with PBS during the initial 
reconstitution step. Methods 2 through 4 differ in the diluent type (PBS or match buffer) and 
timing of the dilution (concurrently with reconstitution or after a 1-hour post-reconstitution 
hold). Method 5 used a partial reconstitution with water and a 10-minute hold prior to diluting in 
match buffer. These methods were hypothesized to improve the membrane integrity of 
rehydrated cells by reducing the osmotic shock compared to method 1. All the subsequent 
methods outperformed method 1 and method 5 (i.e. partial reconstitution method) resulted in the 
highest post-rehydration membrane integrity (84.0 ± 0.2%).  
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Pre-drying: Sample diluted prior to measurement N/A 400 N/A 89.0 ± 2.8 
Method 1: Water and PBS added during 
reconstitution, viability measured after ≥1 h hold 70 400 N/A 59.2 ± 3.5 
Method 2: Water and match buffer added during 
reconstitution, viability measured after ≥1 h hold 70 N/A 400 80.2 ± 2.6 
Method 3: Water added during reconstitution, held 
for 1 h, diluted with PBS, viability measured 70 400 N/A 78.7 ± 5.6 
Method 4: Water added during reconstitution, held 
for 1 h, diluted with match buffer, viability 
measured 
70 N/A 400 77.3 ± 2.1 
Method 5: Water added during reconstitution, held 
for 10 min, diluted with match buffer, viability 
measured after ≥50 min hold 
45 N/A 425 84.0 ± 0.2 
† Match buffer = 30% trehalose, 3% BSA #1 in PBS (pH 7.4); ‡ n = 2; Vial fill volume of 100 μL (with approximately 30% 
solids content) in a 2 mL vial, Dilutions targeted a final volume of 500 μL   
Table 1. Comparison of various reconstitution methods and impact to membrane integrity after 
rehydration. 
 A sample prepared at 1E6 cells/mL was compared to 5E6 cells/mL to test the impact of 
cell concentration on membrane integrity after drying and rehydration (Figure 9). The 1E6 
cells/mL preparation possessed lower membrane integrity after reconstitution using method 1. 
The 5E6 cells/mL preparations exhibited improved tolerability to osmotic shock during 
reconstitution per method 1. However, when dried samples were reconstituted with water and 
diluted with match buffer (30% trehalose, 3% BSA #1 in PBS), there was not a significant 




Figure 9. Impact of cell density and reconstitution method on membrane integrity after vacuum-
foam drying. Data presented as average ± standard deviation (n = 2). 
 An unexpected change in membrane integrity results after drying was observed during 
follow-up experimentation (data not shown). Based on these data, a study was executed to 
determine if the different source of BSA (BSA #2, manufactured by Sigma-Aldrich, see 
Materials & Methods) used in these experiments had a significant impact on cell stabilization. To 
evaluate whether an impurity in one of the BSA sources was leading to 
stabilization/destabilization during drying, cells were dried using a 30% trehalose, 3% albumin 
(in PBS at pH 7.4) formulation with different albumins (BSA #1, BSA #2, and HSA). 
Formulation buffers containing BSA and HSA were dialyzed (Thermo Scientific Slide-A-Lyzer 
Dialysis Cassettes, 7,000 MWCO) against 30% trehalose in PBS to remove any small molecule 
impurities and results were compared to non-dialyzed buffer preparations. All formulations were 
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vacuum-foam dried using the rapid foam drying method to a final residual water content of  
13.4-15.4% (w.b.).  
 Figure 10 shows the membrane integrity results after reconstituting dried foam 
preparations with water and concurrent dilution in match buffer (reconstitution method 2 from 
Table 1). Dialyzed and non-dialyzed BSA #1 formulations possessed significantly higher 
membrane integrity after reconstitution than BSA #2 formulations (dialyzed and non-dialyzed). 
Dialysis of BSA #2 improved final membrane integrity suggesting that an impurity in BSA #2 
may have contributed to cell degradation during drying. However, even dialysis of BSA #2 did 
not yield membrane integrity results comparable to BSA #1, therefore, the small molecule 
impurity was not likely the only factor contributing to instability. The replacement of BSA #1 
with HSA did not have a significant impact on foam drying success or membrane integrity 
suggesting that the common pharmaceutical excipient may be a replacement for BSA. This 
experiment showed similar results between BSA #1 and HSA as well as improved membrane 




Figure 10. Impact of albumin type on T cell membrane integrity after drying for 30% trehalose, 
3% albumin in PBS (pH 7.4) formulations. Membrane integrity of all formulations was measured 
prior to drying and the average (± std, n =2) membrane integrity (%) is presented (black) for 
comparison to results after drying and rehydration (grey). Rehydration was performed using 
reconstitution method 2 (see Table 1).  
 The next step towards producing a stable amorphous human T cell solid was to evaluate 
the impact of residual water content on membrane integrity and glass transition temperature of 
the amorphous matrix. Human T cells incubated for 2 days were formulated with 30% trehalose, 
3% BSA #1 in PBS and dried using the standard foam drying method in a 10 mL vial with a 1 
mL fill volume (approximately 1E6 cells/mL). A reconstitution method similar to method 5 from 
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Table 1 (10 times larger reconstitution/dilution volumes used due to 10 times larger fill volume) 
was used to rehydrate dried foams for membrane integrity testing.  
 Table 2 shows the change in residual water content, glass transition temperature, and 
membrane integrity throughout the drying process. The glass transition temperature of a dried 
product must be higher than the intended storage condition to reduce degradation during 
storage.51  The glass transition temperature of the foam dried material was increased through 
reducing the residual water content.  
 The pre-dried T cell formulation possessed 94.0% membrane integrity. After 45 minutes 
of drying, a sample was removed from the freeze-dryer possessing a residual water content of 
20% (w.b.) and a rehydrated membrane integrity of 88.5%. After 90 minutes of drying, the 
residual water content was reduced to 11.7% (w.b.) and the rehydrated membrane integrity to 
86.5% (less than 1 log10 loss compared to starting formulation). The glass transition temperature 
(midpoint) of the 90-minute sample remained lower than ambient storage (Tg = 12.3 °C). As the 
residual water content was reduced below 10%, the glass transition temperature increased above 
ambient storage, however, the membrane integrity continued to decrease (82.3%). It is possible 
that the reconstitution procedure may have a greater impact to membrane integrity as samples 
become drier; therefore, further optimization of the rehydration method may be needed to 
improve membrane integrity results for lower residual water content samples. 
 Overall, this data demonstrates the need to optimize residual water content to balance 
degradation during drying and a glass transition temperature high enough for convenient storage. 
Figure 11 presents a visualization of this balance by plotting cellular membrane integrity and 
glass transition temperature as a function of residual water content. The data show that high 
levels of membrane integrity can be retained after drying and rehydration.  
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 Attempts to re-grow the cells after rehydration by diluting them in cell growth medium 
and placing in the incubator were unsuccessful. A significant number of cells aggregated and/or 
lysed and no cell growth was observed. One potential reasons for this could be that the cells are 
going through a lipid-phase transition when placed in the 37 °C incubator leading to a leaky 
membrane and cell degradation. Another possible reason is that during dilution, the cells are 
placed in a hypotonic solution (i.e. more solutes such as trehalose inside the cell compared to the 




content (%, w.b.) 
Tg (°C) (onset, 
midpoint) 
Log10 loss in 
membrane integrity 
Membrane integrity 
(%) ± std (n=6) 
0 N/A N/A N/A 94.0 ± 0.4
‡
 
0.75 20.0 not detected 0.74 88.5 ± 2.4 
1.5 11.7 7.8, 12.3 0.88 86.5 ± 2.7 
3 9.4 21.4, 25.8 1.07 82.3 ± 2.7 
6 7.9 28.8, 32.6 1.15 79.9 ± 4.8 
12 6.1 36.7, 42.3 1.36 71.3 ± 6.2 
‡
 n = 3 




Figure 11. Impact of residual water content on membrane integrity and Tg. Membrane integrity 
data presented as average ± standard deviation (n = 2). 
 Figure 11 demonstrates that the dried trehalose-based formulation (30% trehalose, 3% 
BSA in PBS) exhibits a glass transition temperature above refrigeration storage (i.e. 2-8 °C) at 
and below approximately 12% residual water content. Previous work showed that storage 
stability of vacuum-foam dried T cells decreased when stored above their glass transition 
temperature compared to below (data not shown).52 To evaluate the use of various drying 
techniques, human T cells (approximately 2.5E6 cells/mL) were dried using three different 
drying methods; vacuum-foam drying, freeze-drying, and spray freeze-drying. Prior to drying, 
the cells were diluted in complete media (growth media + human serum with IL-6) and incubated 
at 37 °C, 5% CO2 in a culture flask for 3 days. The drying cycles were designed to target 
between approximately 8% to 10% residual water content (see Drying Process Development).  
The residual water content of the dried preparations was 6.5% for freeze-drying, 9.2% for 
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vacuum-foam drying, and 7.6% for spray freeze-drying. The freeze-dried preparations were 
noted to have about 1.5% lower residual water content than the target range and, therefore, 
expected to possess lower membrane integrity after rehydration. 
 Figure 12 shows the appearance of freeze-dried, vacuum-foam dried and spray freeze-
dried T cell preparations in a 10 mL vial.  The freeze-dried preparation exhibited typical cake 
appearance (i.e. no collapse or shrinkage) with minor cracking which is not expected to impact 
product quality.44 Some splashing was observed during the vacuum-foam drying process and is 
visible on the side of the foam dried vial. The atomization step of the spray freeze-drying process 
generates an aerosol that is then frozen and freeze-dried into spherical particles resulting in a 
semi-flowable powder. There were not any significant challenges with reconstitution for any of 
the products. The reconstitution procedure used a partial water reconstitution followed by 
dilution in match buffer after 10 minutes and a 50-minute hold (reconstitution method 5 in Table 
1). Foaming was observed initially after reconstitution of the spray freeze-dried powder that 
dissipated after a few minutes. The reconstitution volumes for the spray freeze-dried preparation 
was adjusted since the powder was filled manually into the vial resulting in powder weight that 





Figure 12. Freeze-dried (left), vacuum-foam dried (center) and spray freeze-dried (right) 
preparations of dried human T cells (Formulation: 30% trehalose, 3% BSA in PBS, pH 7.4). 
 The membrane intergity of each sample was measured and compared to the pre-dried 
control (Figure 13). The membrane integrity of the pre-dried T cell formulation was 91.2±1.5%. 
Vacuum-foam drying resulted in a lower process loss (6.5%) than the freeze-drying (20.4%) and 
spray freeze-drying (64.9%) processes, although, as previously noted, the residual water content 
of the vacuum-foam dried preparation was 1-3% higher. The freeze-dried process loss was 
consistent with the loss observed when vacuum-foam dried preparations were dried to similar 
residual water content (Figure 11). Based on Figure 11, 6-7% residual water content of vacuum-
foam dried preparations resulted in post-rehydration membrane integrity between approximately 
70-75%.  
 The membrane integrity results after 12 weeks of storage at 5 °C demonstrate that the 
vacuum-foam dried material (89.7±1.7%) was significantly more stable than the freeze-dried 
(42.9%) and spray dried (16.3%) material. The improved stability of vacuum-foam dried 
preparations was demonstrated even though all materials were stored below (i.e. >~20 °C) their 
glass transition temperature (Tg estimated based on Figure 11 and residual water content values). 
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Figure 13 demonstrates that T cell membrane integrity can be retained through the vacuum-foam 
drying process and after storage at refrigeration temperature. These data demonstrate improved 
storage stability in foam dried preparations compared to freeze-dried and spray freeze-dried 
preparations. The results are consitent with findings from studies evaluating a monoclonal 
antibody53 and a live attenuated vaccine54 demonstrating the versatility of the process to stabilize 
various therapeutic compounds. The improved storage stability of macromolecules in a dried 
amorphous foam has previously been correlated to reduced specific surface area and molecular 
mobility.42, 53 
 
Figure 13. Membrane integrity of human T cells in 30% trehalose, 3% BSA in PBS, pH 7.4 
formulation after drying and 12 weeks of storage at 5 °C compared to pre-dried control. Data 
presented as average ± standard deviation (n = 3-5). (VFD = vacuum-foam dried; FD = freeze-




 The preservation of human T cell membrane integrity after drying in the amorphous state 
and rehydration required utilization of a systematic approach that evolved as additional 
data/learnings were acquired. Kinetic studies demonstrated the uptake of trehalose into the 
intracellular matrix of T cells when formulated at high trehalose concentrations. Recovering 
post-thawed cells in a 37 °C, 5% CO2 incubator for at least 1 day prior to drying was shown to 
significantly improve post-drying and rehydration membrane integrity. Several studies 
demonstrated that the reconstitution medium and procedure used to rehydrate dried T cell 
preparations have a significant impact on membrane integrity. The residual water content in the 
dried amorphous solid was shown to be a critical factor that needs to balance improved process 
recovery at higher residual water content and increased glass transition temperature at lower 
residual water content. The technique used to dry the cells was also shown to have an impact on 
the process recovery and storage stability of the cells. Vacuum-foam dried preparations exhibited 
reduced process loss and improved storage stability at 2-8 °C compared to freeze-dried and 
spray-freeze dried preparations when formulated in a high concentration trehalose-based 
solution. These findings and fundamental learnings can be used to improve T cell stabilization 
during drying and rehydration in future work. 
 There may be stabilizing excipients not evaluated in this work that are able to improve 
membrane integrity results after drying to lower residual water content values. Drying 
procedures should continue to be optimized to evaluate the use of lower trehalose concentration 
formulations and additional stabilizing excipients. Since membrane integrity is vital to cell 
structure, it was the main attribute assessed in this work to evaluate cell health, however, 
additional work will be required to enable cell re-growth and maintenance of cell functionality 
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(e.g. antigen recognition). Learnings from this work regarding drying procedure and 
reconstitution method can be leveraged in future studies in order to achieve functional 
mammalian cells capable of proliferation after drying and rehydration. The ability to preserve 
human T cells in the dried amorphous state will enable new options for storing and delivering 
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